Gamida Cell Ltd
NASDAQ:GMDA 10:39:21 AM EDT
| Market Cap (Intraday) | 230.18M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $2.18 |
| 50-Day MA | $1.63 |
| 200-Day MA | $1.68 |
Gamida Cell Ltd Stock, NASDAQ:GMDA
116 Huntington Avenue, Givaat Shaul, Boston, Massachusetts 02116
Israel
Phone: +1.713.400.6400
Number of Employees: 146
Description
Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Boston, MA.